SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 2/5/2016 3:16:52 PM - Followers: 168 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference 02/03/2016 09:00:00 AM
CVM News: CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial 02/01/2016 10:00:00 AM
CVM News: CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine 01/25/2016 09:00:00 AM
CVM News: Current Report Filing (8-k) 01/15/2016 04:56:54 PM
CVM News: Amended Current Report Filing (8-k/a) 01/15/2016 04:49:21 PM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#7900   I think the lawyer fees are paid by Foxwoods Man 02/05/16 03:16:52 PM
#7899   Kind of agree. The lawyer costs come trickledownfacists 02/05/16 01:41:08 PM
#7898   Since their (CVM) lawyer costs are basically covered Foxwoods Man 02/05/16 01:37:41 PM
#7897   I am still thinking that it's in the trickledownfacists 02/05/16 12:53:14 PM
#7896   Yup, arbitration. Looking for a firm date. trickledownfacists 02/05/16 08:24:25 AM
#7895   Let's hope our lawyers are better than their Paleman 02/05/16 07:17:36 AM
#7894   Last thing I heard - the Arbitration date drkazmd65 02/05/16 07:13:14 AM
#7893   Exactly! If it does go forward this time Foxwoods Man 02/05/16 06:40:54 AM
#7892   I am waiting to hear if the Arbitration drkazmd65 02/04/16 11:57:57 PM
#7891   question for board. What would have to happen Turney 02/04/16 06:56:22 PM
#7890   Cel-Sci Corp. ($0.00 (CVM) 0.4704 ? 0.005 (1.07%) mick 02/04/16 01:07:08 PM
#7889   Thrilling Phase III Cancer Immunotherapy Comeback and the trickledownfacists 02/04/16 09:47:15 AM
#7888   You are right, it all takes time, just ed2000 02/04/16 09:31:34 AM
#7887   6 months or so sounds close for completing Foxwoods Man 02/04/16 09:25:51 AM
#7886   6 months, and they should fill their patient ed2000 02/04/16 09:18:19 AM
#7885   CEL-SCI to Present at 18th Annual BIO CEO trickledownfacists 02/03/16 11:44:23 AM
#7884   Baby steps....need to get the stuff presently on Foxwoods Man 02/02/16 05:43:43 PM
#7883   Thoughts on if Geert will try any sort trickledownfacists 02/02/16 04:16:00 PM
#7882   Thanks. Why do they need so many patients ? Investor_cmz 02/02/16 08:15:39 AM
#7881   I assume the worse case scenario. Geert ducruacuteo11 02/01/16 07:22:52 PM
#7880   I assume that they will need two Foxwoods Man 02/01/16 04:21:11 PM
#7879   Ergomed eyes more drug deals as revenues rise Pharma trickledownfacists 02/01/16 02:28:52 PM
#7878   You got that right! If they eliminate ducruacuteo11 02/01/16 02:23:26 PM
#7877   I think it is safe to say that Foxwoods Man 02/01/16 02:12:20 PM
#7876   29 enrolled 697 total trickledownfacists 02/01/16 10:05:37 AM
#7875   www.stockscores.com/chart.asp?TickerSymbol=cvm&TimeRange=180&Interval=d&V mick 01/31/16 11:59:36 AM
#7874   Yup, those are the reasons. trickledownfacists 01/30/16 05:18:36 PM
#7873   Maybe because it is already approved for treatment Foxwoods Man 01/30/16 03:54:56 PM
#7872   Can someone explain how Somethink like checkmate 141 Investor_cmz 01/30/16 02:28:09 PM
#7871   Well I officially retire from guessing what CVM Turney 01/29/16 04:06:01 PM
#7870   ...and down to 0.155 as CVM is up Foxwoods Man 01/29/16 03:17:31 PM
#7869   It would be interesting if we have a Turney 01/29/16 01:31:01 PM
#7868   Experiment failed. I put some warrants out there Foxwoods Man 01/29/16 11:32:06 AM
#7867   As expected....back to 0.25 Foxwoods Man 01/29/16 09:34:27 AM
#7866   Hmmmm...I just had an idea...I'll report back in Foxwoods Man 01/29/16 08:26:12 AM
#7865   I though the same, and it will most trickledownfacists 01/29/16 08:23:46 AM
#7864   This makes zero sense to me...why would anyone Foxwoods Man 01/29/16 07:18:23 AM
#7863   Sombody appears to have bought a boat load Turney 01/29/16 02:28:33 AM
#7862   Warrants up 135%? trickledownfacists 01/28/16 05:10:03 PM
#7861   It'll be above 32 and under 43. trickledownfacists 01/28/16 12:04:27 AM
#7860   I am going to be conservative and guess Foxwoods Man 01/27/16 12:54:10 PM
#7859   So - now we are about a week drkazmd65 01/27/16 12:33:24 PM
#7858   Indeed,.... very nice way to start the week. drkazmd65 01/25/16 10:13:07 AM
#7857   CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine Sou trickledownfacists 01/25/16 10:12:38 AM
#7856   Ohhh weee. trickledownfacists 01/25/16 10:03:56 AM
#7855   Beware pre market trading here. I've seen trickledownfacists 01/25/16 08:48:06 AM
#7854   Solid week. trickledownfacists 01/22/16 04:05:40 PM
#7853   ON THE MARKET: 3 Million Share Insider Buy trickledownfacists 01/22/16 01:52:57 PM
#7852   Today there is an nice article about Cel-Sci MsMom1 01/22/16 01:26:01 PM
#7851   Over on yahoo board a post says infection Turney 01/22/16 07:15:18 AM
PostSubject